These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 21193036)

  • 1. The development of a whole-cell based medium throughput screening system for the discovery of human aldosterone synthase (CYP11B2) inhibitors: old drugs disclose new applications for the therapy of congestive heart failure, myocardial fibrosis and hypertension.
    Hakki T; Hübel K; Waldmann H; Bernhardt R
    J Steroid Biochem Mol Biol; 2011 May; 125(1-2):120-8. PubMed ID: 21193036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of test systems for the discovery of selective human aldosterone synthase (CYP11B2) and 11beta-hydroxylase (CYP11B1) inhibitors. Discovery of a new lead compound for the therapy of congestive heart failure, myocardial fibrosis and hypertension.
    Bureik M; Hübel K; Dragan CA; Scher J; Becker H; Lenz N; Bernhardt R
    Mol Cell Endocrinol; 2004 Mar; 217(1-2):249-54. PubMed ID: 15134825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The adrenocortical tumor cell line NCI-H295R as an in vitro screening system for the evaluation of CYP11B2 (aldosterone synthase) and CYP11B1 (steroid-11beta-hydroxylase) inhibitors.
    Müller-Vieira U; Angotti M; Hartmann RW
    J Steroid Biochem Mol Biol; 2005 Aug; 96(3-4):259-70. PubMed ID: 15985365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of CYP11B1 and CYP11B2 assays utilizing homogenates of adrenal glands: Utility of monkey as a surrogate for human.
    Cerny MA; Csengery A; Schmenk J; Frederick K
    J Steroid Biochem Mol Biol; 2015 Nov; 154():197-205. PubMed ID: 26303746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of selective CYP11B2 (aldosterone synthase) inhibitors for the therapy of congestive heart failure and myocardial fibrosis.
    Hartmann RW; Müller U; Ehmer PB
    Eur J Med Chem; 2003 Apr; 38(4):363-6. PubMed ID: 12750023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a test system for inhibitors of human aldosterone synthase (CYP11B2): screening in fission yeast and evaluation of selectivity in V79 cells.
    Ehmer PB; Bureik M; Bernhardt R; Müller U; Hartmann RW
    J Steroid Biochem Mol Biol; 2002 Jun; 81(2):173-9. PubMed ID: 12137808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis.
    Voets M; Antes I; Scherer C; Müller-Vieira U; Biemel K; Barassin C; Marchais-Oberwinkler S; Hartmann RW
    J Med Chem; 2005 Oct; 48(21):6632-42. PubMed ID: 16220979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heteroatom insertion into 3,4-dihydro-1H-quinolin-2-ones leads to potent and selective inhibitors of human and rat aldosterone synthase.
    Grombein CM; Hu Q; Rau S; Zimmer C; Hartmann RW
    Eur J Med Chem; 2015 Jan; 90():788-96. PubMed ID: 25528333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potential of targeting CYP11B.
    Bernhardt R
    Expert Opin Ther Targets; 2016 Aug; 20(8):923-34. PubMed ID: 26854589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase.
    Ulmschneider S; Müller-Vieira U; Mitrenga M; Hartmann RW; Oberwinkler-Marchais S; Klein CD; Bureik M; Bernhardt R; Antes I; Lengauer T
    J Med Chem; 2005 Mar; 48(6):1796-805. PubMed ID: 15771425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective aldosterone synthase inhibitors reduce aldosterone formation in vitro and in vivo.
    Ries C; Lucas S; Heim R; Birk B; Hartmann RW
    J Steroid Biochem Mol Biol; 2009 Sep; 116(3-5):121-6. PubMed ID: 19427380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a high-throughput assay for aldosterone synthase inhibitors using high-performance liquid chromatography-tandem mass spectrometry.
    Yurek D; Yu L; Schrementi J; Bell MG; McGee J; Kowala M; Kuo MS; Wang J
    Anal Biochem; 2014 Oct; 462():44-50. PubMed ID: 24959941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A steady state system for in vitro evaluation of steroidogenic pathway dynamics: Application for CYP11B1, CYP11B2 and CYP17 inhibitors.
    Mangelis A; Jühlen R; Dieterich P; Peitzsch M; Lenders JWM; Hahner S; Schirbel A; Eisenhofer G
    J Steroid Biochem Mol Biol; 2019 Apr; 188():38-47. PubMed ID: 30529282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of N-[5-(6-Chloro-3-cyano-1-methyl-1H-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, a Cortisol-Sparing CYP11B2 Inhibitor that Lowers Aldosterone in Human Subjects.
    Papillon JP; Lou C; Singh AK; Adams CM; Ksander GM; Beil ME; Chen W; Leung-Chu J; Fu F; Gan L; Hu CW; Jeng AY; LaSala D; Liang G; Rigel DF; Russell KS; Vest JA; Watson C
    J Med Chem; 2015 Dec; 58(23):9382-94. PubMed ID: 26540564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical and Early Clinical Profile of a Highly Selective and Potent Oral Inhibitor of Aldosterone Synthase (CYP11B2).
    Bogman K; Schwab D; Delporte ML; Palermo G; Amrein K; Mohr S; De Vera Mudry MC; Brown MJ; Ferber P
    Hypertension; 2017 Jan; 69(1):189-196. PubMed ID: 27872236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldosterone synthase inhibition in humans.
    Azizi M; Amar L; Menard J
    Nephrol Dial Transplant; 2013 Jan; 28(1):36-43. PubMed ID: 23045428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase.
    Ulmschneider S; Müller-Vieira U; Klein CD; Antes I; Lengauer T; Hartmann RW
    J Med Chem; 2005 Mar; 48(5):1563-75. PubMed ID: 15743198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The establishment of a novel high-throughput screening system using RNA-guided genome editing to identify chemicals that suppress aldosterone synthase expression.
    Ito R; Morita M; Nakano T; Sato I; Yokoyama A; Sugawara A
    Biochem Biophys Res Commun; 2021 Jan; 534():672-679. PubMed ID: 33220920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aldosterone synthase (CYP11B2) expression and myocardial fibrosis in the failing human heart.
    Satoh M; Nakamura M; Saitoh H; Satoh H; Akatsu T; Iwasaka J; Masuda T; Hiramori K
    Clin Sci (Lond); 2002 Apr; 102(4):381-6. PubMed ID: 11914098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis.
    Voets M; Antes I; Scherer C; Müller-Vieira U; Biemel K; Marchais-Oberwinkler S; Hartmann RW
    J Med Chem; 2006 Apr; 49(7):2222-31. PubMed ID: 16570918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.